KLRB1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue lysate, Primary antibody: P01174(KLRB1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P01174(KLRB1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P01174(KLRB1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

KLRB1 antibodies target the protein encoded by the *KLRB1* gene, which is a C-type lectin receptor also known as CD161. This transmembrane glycoprotein is primarily expressed on natural killer (NK) cells, subsets of T cells (including mucosal-associated invariant T cells and type 17 helper T cells), and innate lymphoid cells. CD161 interacts with lectin-like ligands such as CLEC2D, playing roles in immune regulation, cell adhesion, and modulation of inflammatory responses.

Antibodies against KLRB1 are widely used in research to identify and characterize immune cell populations, particularly in studies involving viral infections, cancer, autoimmune diseases, and chronic inflammation. For example, KLRB1+ cells are implicated in mucosal immunity and tissue-specific immune responses, making these antibodies valuable in exploring gut, liver, or lung-related pathologies. In cancer immunology, KLRB1 expression is associated with both pro- and anti-tumor functions, depending on context, and may serve as a biomarker for immune cell exhaustion or activation.

Commercial KLRB1 antibodies are optimized for techniques like flow cytometry, immunohistochemistry, and Western blot. Their specificity and applications continue to evolve with ongoing research into CD161's dual roles in promoting immune tolerance and mediating pathogen defense.